Skip to main content
Tech.euFundingExplorerBeta

VERIGRAFT

VERIGRAFT generates personalized tissue-engineered transplants for use in regenerative medicine. The company’s unique technology platform turns donated allogeneic (“foreign”) tissue into an autologous-like (“personalized”) tissue and thus avoids transplant rejection and the need for life-long immunosuppression.

Total raised
€1.2M
€1,200,000
Funding rounds
1
Investors
1
distinct backers
Active since
2025-02
latest 2025-02

Funding by year

EUR raised per year

Signals

High confidence
Raise-next likelihood50
base rate 45% for Grant
  • In typical raise window
  • Low backer re-investment

Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.

Funding rounds

1 rounds
DateStageAmountInvestors
2025-02-14Grant€1.2MEuroStarsView deal →

Investors

1

Related news

Similar companies

same sector or country